William M. Abraham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William M. Abraham has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Ashfaq Ahmed
Division of Pulmonary Disease and Critical Care Medicine, Miller School of Medicine, University of Miami at Mount Sinai Medical Center; and Department of Neonatology, Mount Sinai Medical Center, Miami Beach, Florida
6 shared publicationsIrakli Serebriakov
Division of Pulmonary Disease and Critical Care Medicine, Miller School of Medicine, University of Miami at Mount Sinai Medical Center; and Department of Neonatology, Mount Sinai Medical Center, Miami Beach, Florida
4 shared publicationsIsabel T. Lauredo
Division of Pulmonary Disease and Critical Care Medicine, Miller School of Medicine, University of Miami at Mount Sinai Medical Center; and Department of Neonatology, Mount Sinai Medical Center, Miami Beach, Florida
4 shared publications- Tahir Ahmed
Pulmonary Division, Mount Sinai Medical Center, Miami Beach, Florida, USA
4 shared publications Daniel G. Baden
3 shared publications- Gregory Smith
Department of Research, Mount Sinai Medical Center, 4300 Alton Rd. Miami Beach, Miami Beach, FL 33140, USA
3 shared publications
Latest Publications
- 1 June 2014
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 28 (1) , 77-86
Heparin-derived supersulfated disaccharide inhibits allergic airway responses in sheep
- 1 June 2014
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 28 (1) , 77-86
Heparin-derived supersulfated disaccharide inhibits allergic airway responses in sheep
- 18 October 2012
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 26 (2) , 180-188
Effect of oral and intravenous heparin tetrasaccharide on allergic airway responses: Critical role of N-sulfation
- 18 October 2012
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 26 (2) , 180-188
Effect of oral and intravenous heparin tetrasaccharide on allergic airway responses: Critical role of N-sulfation
- Open Access
- 23 January 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 6
Inhibition of allergic airway responses by heparin derived oligosaccharides: identification of a tetrasaccharide sequence
Background: Previous studies showed that heparin's anti-allergic activity is molecular weight dependent and resides in oligosaccharide fractions of Ascaris suumantigen with and without inhaled oligosaccharide pretreatment and the effects on specific lung resistance and airway hyperresponsiveness (AHR) to carbachol determined. Additional inflammatory cell recruitment studies were performed in immunized ovalbumin-challenged BALB/C mice with and without treatment.Results: The inhaled tetrasaccharide fraction was the minimal effective chain length to show anti-allergic activity. This fraction showed activity in both groups of sheep; it was also effective in inhibiting LAR and AHR, when administered after the antigen challenge. Tetrasaccharide failed to modify the bronchoconstrictor responses to airway smooth muscle agonists (histamine, carbachol and LTD4), and had no effect on antigen-induced histamine release in bronchoalveolar lavage fluid in sheep. In mice, inhaled tetrasaccharide also attenuated the ovalbumin-induced peribronchial inflammatory response and eosinophil influx in the bronchoalveolar lavage fluid. Chemical analysis identified the active structure to be a pentasulfated tetrasaccharide ([IdoU2S (1→4)GlcNS6S (1→4) IdoU2S (1→4) AMan-6S]) which lacked anti-coagulant activity.Conclusions: These results demonstrate that heparin tetrasaccharide possesses potent anti-allergic and anti-inflammatory properties, and that the domains responsible for anti-allergic and anti-coagulant activity are distinctly different.
- 23 January 2012
- Published by Springer Nature in Respiratory Research
- Vol. 13 (1) , 6
Open AccessInhibition of allergic airway responses by heparin derived oligosaccharides: identification of a tetrasaccharide sequence
Background: Previous studies showed that heparin's anti-allergic activity is molecular weight dependent and resides in oligosaccharide fractions of Ascaris suumantigen with and without inhaled oligosaccharide pretreatment and the effects on specific lung resistance and airway hyperresponsiveness (AHR) to carbachol determined. Additional inflammatory cell recruitment studies were performed in immunized ovalbumin-challenged BALB/C mice with and without treatment.Results: The inhaled tetrasaccharide fraction was the minimal effective chain length to show anti-allergic activity. This fraction showed activity in both groups of sheep; it was also effective in inhibiting LAR and AHR, when administered after the antigen challenge. Tetrasaccharide failed to modify the bronchoconstrictor responses to airway smooth muscle agonists (histamine, carbachol and LTD4), and had no effect on antigen-induced histamine release in bronchoalveolar lavage fluid in sheep. In mice, inhaled tetrasaccharide also attenuated the ovalbumin-induced peribronchial inflammatory response and eosinophil influx in the bronchoalveolar lavage fluid. Chemical analysis identified the active structure to be a pentasulfated tetrasaccharide ([IdoU2S (1→4)GlcNS6S (1→4) IdoU2S (1→4) AMan-6S]) which lacked anti-coagulant activity.Conclusions: These results demonstrate that heparin tetrasaccharide possesses potent anti-allergic and anti-inflammatory properties, and that the domains responsible for anti-allergic and anti-coagulant activity are distinctly different.
- 1 October 2008
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 21 (5) , 743-754
Modeling of asthma, COPD and cystic fibrosis in sheep
- 1 October 2008
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 21 (5) , 743-754
Modeling of asthma, COPD and cystic fibrosis in sheep
- 1 October 2006
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 174 (7) , 743-752
Whole-Body Periodic Acceleration Modifies Experimental Asthma in Sheep
Rationale: Nitric oxide is released from vascular endothelium in response to increased pulsatile shear stress. Nitric oxide inhibits mast cell activation and is antiinflammatory and therefore might be protective in asthma. Objectives: We determined if a noninvasive motion platform that imparts periodic sinusoidal inertial forces to the whole body along the spinal axis (pGz) causing release of endothelial nitric oxide modulates experimental asthma in sheep. Methods: Allergic sheep were untreated (control) or were treated with pGz alone or after receiving intravenously the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) before aerosol challenge with Ascaris suum, and the effect on antigen-induced airway responses was determined. Bronchoalveolar lavage cells obtained 6 h after antigen challenge were analyzed for nuclear factor-κB (NF-κB) activity in the respective groups. Results: pGz treatment for 1 h before antigen challenge reduced the early airway response and blocked the late airway response but did not prevent the antigen-induced airway hyperresponsiveness 24 h after challenge. Administration of L-NAME before pGz completely reversed this protection, whereas L-NAME alone did not affect the antigen-induced responses. NF-κB activity was 1.9- and 1.8-fold higher in the control and L-NAME + pGz groups, respectively, compared with pGz-treated animals. Extending the pGz treatment to twice daily for 3 d and then 1 h before antigen challenge blocked the early and late airway responses, the 24-h airway hyperresponsiveness, and the airway inflammatory cell response. Conclusion: Whole-body pGz modulates allergen-induced airway responses in allergic sheep.
- 1 October 2006
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 174 (7) , 743-752
Whole-Body Periodic Acceleration Modifies Experimental Asthma in Sheep
Rationale: Nitric oxide is released from vascular endothelium in response to increased pulsatile shear stress. Nitric oxide inhibits mast cell activation and is antiinflammatory and therefore might be protective in asthma. Objectives: We determined if a noninvasive motion platform that imparts periodic sinusoidal inertial forces to the whole body along the spinal axis (pGz) causing release of endothelial nitric oxide modulates experimental asthma in sheep. Methods: Allergic sheep were untreated (control) or were treated with pGz alone or after receiving intravenously the nitric oxide synthase inhibitor Nw-nitro-L-arginine methyl ester (L-NAME) before aerosol challenge with Ascaris suum, and the effect on antigen-induced airway responses was determined. Bronchoalveolar lavage cells obtained 6 h after antigen challenge were analyzed for nuclear factor-κB (NF-κB) activity in the respective groups. Results: pGz treatment for 1 h before antigen challenge reduced the early airway response and blocked the late airway response but did not prevent the antigen-induced airway hyperresponsiveness 24 h after challenge. Administration of L-NAME before pGz completely reversed this protection, whereas L-NAME alone did not affect the antigen-induced responses. NF-κB activity was 1.9- and 1.8-fold higher in the control and L-NAME + pGz groups, respectively, compared with pGz-treated animals. Extending the pGz treatment to twice daily for 3 d and then 1 h before antigen challenge blocked the early and late airway responses, the 24-h airway hyperresponsiveness, and the airway inflammatory cell response. Conclusion: Whole-body pGz modulates allergen-induced airway responses in allergic sheep.
- Open Access
- 1 June 2006
- Published by The Oceanography Society in Oceanography
- Vol. 19 (2) , 107-109
Aerosolized Florida Red Tide Toxins and Human Health Effects
- 1 June 2006
- Published by The Oceanography Society in Oceanography
- Vol. 19 (2) , 107-109
Open AccessAerosolized Florida Red Tide Toxins and Human Health Effects
- 1 March 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 533 (1-3) , 215-221
Peptide and non-peptide bradykinin receptor antagonists: Role in allergic airway disease
- 1 March 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 533 (1-3) , 215-221
Peptide and non-peptide bradykinin receptor antagonists: Role in allergic airway disease
- Open Access
- 1 May 2005
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 113 (5) , 632-637
Effects of Inhaled Brevetoxins in Allergic Airways: Toxin–Allergen Interactions and Pharmacologic Intervention
During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway disease (e.g., asthma). To understand these toxin-induced airway ...
- 1 May 2005
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 113 (5) , 632-637
Open AccessEffects of Inhaled Brevetoxins in Allergic Airways: Toxin–Allergen Interactions and Pharmacologic Intervention
During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway disease (e.g., asthma). To understand these toxin-induced airway ...
- 1 January 2005
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 171 (1) , 26-34
Airway Responses to Aerosolized Brevetoxins in an Animal Model of Asthma
10.1164/rccm.200406-735OC Florida red tide brevetoxins are sodium channel neurotoxins produced by the dinoflagellate Karenia brevis. When aerosolized, the toxin causes airway symptoms in normal individuals and patients with airway disease, but systematic exposures to define the pulmonary consequences and putative mechanisms are lacking. Here we report the effects of airway challenges with lysed cultures of Karenia brevis (crude brevetoxin), pure brevetoxin-2, brevetoxin-3, and brevetoxin-tbm (brevetoxin-2 minus the side chain) on pulmonary resistance and tracheal mucus velocity, a marker of mucociliary clearance, in allergic and nonallergic sheep. Picogram concentrations of toxin caused bronchoconstriction in both groups of sheep. Brevetoxin-tbm was the least potent, indicating the importance of the side chain for maximum effect. Both histamine H1– and cholinergic-mediated pathways contributed to the bronchoconstriction. A synthetic antagonist, β-naphthoyl-brevetoxin-3, and brevenal, a natural antagonist, inhibited the bronchoconstriction. Only crude brevetoxin and brevetoxin-3 decreased tracheal mucus velocity; both antagonists prevented this. More importantly, picomolar concentrations of the antagonists alone improved tracheal mucus velocity to the degree seen with mM concentrations of the sodium channel blocker amiloride. Thus, Karenia brevis, in addition to producing toxins that adversely affect the airways, may be a source of agents for treating mucociliary dysfunction.
- 1 January 2005
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 171 (1) , 26-34
Airway Responses to Aerosolized Brevetoxins in an Animal Model of Asthma
10.1164/rccm.200406-735OC Florida red tide brevetoxins are sodium channel neurotoxins produced by the dinoflagellate Karenia brevis. When aerosolized, the toxin causes airway symptoms in normal individuals and patients with airway disease, but systematic exposures to define the pulmonary consequences and putative mechanisms are lacking. Here we report the effects of airway challenges with lysed cultures of Karenia brevis (crude brevetoxin), pure brevetoxin-2, brevetoxin-3, and brevetoxin-tbm (brevetoxin-2 minus the side chain) on pulmonary resistance and tracheal mucus velocity, a marker of mucociliary clearance, in allergic and nonallergic sheep. Picogram concentrations of toxin caused bronchoconstriction in both groups of sheep. Brevetoxin-tbm was the least potent, indicating the importance of the side chain for maximum effect. Both histamine H1– and cholinergic-mediated pathways contributed to the bronchoconstriction. A synthetic antagonist, β-naphthoyl-brevetoxin-3, and brevenal, a natural antagonist, inhibited the bronchoconstriction. Only crude brevetoxin and brevetoxin-3 decreased tracheal mucus velocity; both antagonists prevented this. More importantly, picomolar concentrations of the antagonists alone improved tracheal mucus velocity to the degree seen with mM concentrations of the sodium channel blocker amiloride. Thus, Karenia brevis, in addition to producing toxins that adversely affect the airways, may be a source of agents for treating mucociliary dysfunction.
- 1 April 2004
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 286 (4) , L734-L740
Leukocytic cell sources of airway tissue kallikrein
Lung tissue kallikrein (TK) is a serine proteinase that putatively plays a role in the pathophysiology of asthma by generating kallidin and bradykinin, mediators that contribute to airway hyperresponsiveness. In previous studies we observed biphasic increases in TK activity in bronchoalveolar lavage fluid following airway allergen challenge in allergic sheep. Although glandular TK is likely a major source of the initial increase in TK, the sources of the late increases in TK that are associated with the development of airway hyperresponsiveness may be dependent on activated resident and recruited inflammatory cells including alveolar macrophages (AMs) and neutrophils (PMNs). These cells increase concomitantly with the late increases in TK activity. To test this hypothesis, we obtained AMs from bronchoalveolar lavage fluid and PMNs and monocytes (precursors of AMs) from sheep blood and determined whether these cells contained TK and whether these same cells could release TK upon activation. Using confocal microscopy, immunocytochemical techniques, and enzyme activity assays, we found that all three cell types contained and secreted TK. All three cell types demonstrated basal release of TK, which could be increased after stimulation with zymosan. In addition, PMNs also released TK in the presence of phorbol ester, suggesting multiple secretory pathways in these cells. Furthermore, we showed that human monocytes also contain and secrete TK. We conclude that in the airways, monocytes, PMNs, and AMs may contribute to increased TK activity. Knowing the sources of TK in the airways could be important in understanding the mechanisms of inflammation that contribute to the pathophysiology of asthma and may help in the development of new therapies to control the disease.
- 1 April 2004
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 286 (4) , L734-L740
Leukocytic cell sources of airway tissue kallikrein
Lung tissue kallikrein (TK) is a serine proteinase that putatively plays a role in the pathophysiology of asthma by generating kallidin and bradykinin, mediators that contribute to airway hyperresponsiveness. In previous studies we observed biphasic increases in TK activity in bronchoalveolar lavage fluid following airway allergen challenge in allergic sheep. Although glandular TK is likely a major source of the initial increase in TK, the sources of the late increases in TK that are associated with the development of airway hyperresponsiveness may be dependent on activated resident and recruited inflammatory cells including alveolar macrophages (AMs) and neutrophils (PMNs). These cells increase concomitantly with the late increases in TK activity. To test this hypothesis, we obtained AMs from bronchoalveolar lavage fluid and PMNs and monocytes (precursors of AMs) from sheep blood and determined whether these cells contained TK and whether these same cells could release TK upon activation. Using confocal microscopy, immunocytochemical techniques, and enzyme activity assays, we found that all three cell types contained and secreted TK. All three cell types demonstrated basal release of TK, which could be increased after stimulation with zymosan. In addition, PMNs also released TK in the presence of phorbol ester, suggesting multiple secretory pathways in these cells. Furthermore, we showed that human monocytes also contain and secrete TK. We conclude that in the airways, monocytes, PMNs, and AMs may contribute to increased TK activity. Knowing the sources of TK in the airways could be important in understanding the mechanisms of inflammation that contribute to the pathophysiology of asthma and may help in the development of new therapies to control the disease.